Novo Nordisk CEO warns of layoffs as Wegovy challenge heats up

Novo Nordisk is facing significant pressure on its blockbuster obesity drug Wegovy due to intense competition from Eli Lilly's Zepbound and persistent, lower-priced compounded versions, prompting its CEO to warn of potential layoffs. The company recently cut its full-year sales and profit forecasts, wiping $95 billion off its market value and causing shares to plunge 30% last week, as the anticipated decline in compounded GLP-1 usage post-FDA ban has not materialized. Novo is implementing cost-cutting measures, including R&D project terminations, and expects deeper U.S. pricing erosion despite robust international growth.

Analysis

Novo Nordisk is confronting a significant and abrupt reversal in its growth trajectory, driven by intensifying competition and persistent market challenges for its blockbuster obesity drug, Wegovy. The company's recent decision to cut its full-year sales and profit forecasts, which erased $95 billion from its market value and triggered a 30% stock plunge, underscores the severity of the situation. The primary headwinds are twofold: aggressive market share gains by Eli Lilly's rival drug Zepbound, and the unexpectedly resilient market for lower-priced compounded GLP-1 drugs. Despite a U.S. FDA ban, over one million patients continue to use these copycat versions, a factor Novo's revised outlook now incorporates after previously assuming their decline. In response, management is signaling potential layoffs and has initiated cost-cutting by terminating eight R&D projects. While second-quarter sales saw a 36% rise in the U.S. and quadrupled internationally, the company anticipates deeper pricing erosion in the key U.S. market during the second half of the year, a risk that could lead to negative year-over-year growth in H2 2025 under the low end of its new guidance.

Key Decisions for Investors

• The investment thesis for Novo Nordisk has fundamentally shifted from unchecked growth to one of significant market share defense and margin pressure; investors should re-evaluate long positions in light of the new competitive landscape.
• Closely monitor weekly U.S. prescription data for Wegovy versus Eli Lilly's Zepbound and any regulatory updates on compounded GLP-1s, as these are now the primary drivers of near-term revenue and sentiment.
• Assess the potential impact of announced cost-cutting measures and R&D project terminations on the company's long-term innovation pipeline and competitive positioning.
• Given the starkly negative sentiment for Novo Nordisk and positive sentiment for Eli Lilly, consider the relative strength of Lilly as a key risk factor and potentially a more favorable exposure to the GLP-1 market.